NCT06834360

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2025-02-06Est. Completion: 2026-09-24

Enrollment target: 216 participants

Locations

Excel ENT of Alabama- Site Number : 8400052, Birmingham, Alabama, United States
Velocity Clinical Research - San Diego- Site Number : 8400041, La Mesa, California, United States
Cedars-Sinai Medical Center- Site Number : 8400030, Los Angeles, California, United States
One Of A Kind Clinical Research Center- Site Number : 8400034, Napa, California, United States
University of Florida - Jacksonville- Site Number : 8400053, Jacksonville, Florida, United States
Advanced Research Institute - New Port Richey- Site Number : 8400014, New Port Richey, Florida, United States
University of Illinois at Chicago- Site Number : 8400003, Chicago, Illinois, United States
Advanced ENT & Allergy - Louisville- Site Number : 8400007, Louisville, Kentucky, United States
Velocity Clinical Research - Lafayette- Site Number : 8400026, Lafayette, Louisiana, United States
Johns Hopkins Hospital- Site Number : 8400017, Baltimore, Maryland, United States
University of Cincinnati Medical Center- Site Number : 8400022, Cincinnati, Ohio, United States
Allergy, Asthma and Clinical Research- Site Number : 8400002, Oklahoma City, Oklahoma, United States

Chronic SinusitisNasal Polyposis

Chronic rhinosinusitis with nasal polyps is a condition that causes long-lasting inflammation and swelling in the nose a…

Multiple LocationsEst. completion Oct 14, 2027

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

PETRICHOR is a prospective, non-interventional, single-arm, multi-centre study in Germany evaluating real-world clinical…

Berlin, GermanyEst. completion Dec 31, 2029

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.